Month: September 2021

Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update

– Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 – Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half …

Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update Read More »

Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Sep 27, 2021, 07:30 ET CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the presentation of the protective effects of melanocortin 1 receptor agonists PL8331 and PL9654 in mouse models …

Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting Read More »

Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021

Sep 24, 2021, 07:30 ET CRANBURY, N.J., Sept. 24, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted …

Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021 Read More »

Palatin to Present Peptides Platform at the TIDES USA Conference

– CEO to present Palatin’s world-class expertise in melanocortins and discuss its agonist programs to treat inflammation – Head of Preclinical Research to present posters on the utility of melanocortins to treat inflammation and specific data in an inflammatory disease model Sep 15, 2021, 07:30 ET CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ — Palatin Technologies, Inc. …

Palatin to Present Peptides Platform at the TIDES USA Conference Read More »

Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Sep 13, 2021, 07:00 ET CRANBURY, N.J., Sept. 13, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright 23rd …

Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference Read More »

Scroll to Top